FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897565443> ?p ?o ?g. }

• W2897565443 abstract "Background: Statins are the corner stone therapy of atherosclerotic cardiovascular disease (ASCVD). Statins may cause myalgia, myotoxicity, myopathy and rhabdomyolysis along with its lipid lowering properties and pleiotropic effects. Statins associated muscle symptoms (SAMS) are the leading cause of nonadherent and discontinuation. This study was conducted to evaluate and understand the muscle symptoms of high intensity statin therapy (atorvastatin 40 mg and rosuvastatin 20 mg) for a period of three months in individual patient with clinical atherosclerotic cardiovascular disease.Methods: A total of 280 patients with clinical atherosclerotic cardiovascular disease were studied to once daily atorvastatin 40 mg and rosuvastatin 20 mg. It was a randomized controlled single blind trial. The primary end point was muscle symptoms-muscle pain, fatigue, cramp/spasticity and weakness at 4 weeks and in 3 months of study period. Serum creatinine kinase was measured in every patient with muscular symptoms.Results: Patients of atorvastatin group noticed severe pain more than rosuvastatin group at the end of 3 months of treatment period (14.21% vs 4.38%, p <0.05), respectively). Significantly more patients felt extremely bad (12.78% vs 4.38%, p <0.05) and bad (24.66% vs 14.52%, p <0.05) with atorvastatin compared with rosuvastatin. Patients of atorvastatin group showed more marked increase muscle spasm (3.76% vs 1.46%, p <0.05) and slight increase muscle spasm (36.27% vs 16.01%, p <0.05) than rosuvastatin group by spasticity grade. One patient of atorvastatin group developed considerable increase in muscle spasm. Medical research council (MRC) muscle power grade 4 between atorvastatin and rosuvastatin group was observed 20.05% vs 10.90%, p <0.05, respectively. Three patients of atorvastatin group developed grade 3 muscle power. Serum creatine kinase > 1500 U/L was observed more in atorvastatin than rosuvastatin group (14.21% vs 4.38%, p <0.05, respectively). Statin associated muscle symptoms (more severe muscle problem, myositis/myopathy) observed more in atorvastatin than that of rosuvastatin group ( 34.07% vs 13.08% , p <0.05, respectively). Both treatments were well tolerated. No cases of rhabdomyolysis, incident diabetes, hepatic or renal insufficiency were recorded during the study period.Conclusion: Rosuvastatin had better outcome profile of muscle symptoms than atorvastatin in patients with clinical atherosclerotic cardiovascular disease among the Bangladeshi population. Patients in atorvastatin group experienced more muscle pain, fatigue, cramp/spasticity and weakness than rosuvastatin.University Heart Journal Vol. 14, No. 1, Jan 2018; 9-20" @default.
• W2897565443 created "2018-10-26" @default.
• W2897565443 creator A5001077611 @default.
• W2897565443 creator A5003431303 @default.
• W2897565443 creator A5009415605 @default.
• W2897565443 creator A5010446824 @default.
• W2897565443 creator A5012533751 @default.
• W2897565443 creator A5014392312 @default.
• W2897565443 creator A5018339761 @default.
• W2897565443 creator A5023019606 @default.
• W2897565443 creator A5025787924 @default.
• W2897565443 creator A5026922768 @default.
• W2897565443 creator A5035235024 @default.
• W2897565443 creator A5042097310 @default.
• W2897565443 creator A5056130710 @default.
• W2897565443 creator A5056459550 @default.
• W2897565443 creator A5057599788 @default.
• W2897565443 creator A5057698582 @default.
• W2897565443 creator A5059169044 @default.
• W2897565443 creator A5064330411 @default.
• W2897565443 creator A5074373105 @default.
• W2897565443 creator A5078062998 @default.
• W2897565443 creator A5081471788 @default.
• W2897565443 creator A5081637195 @default.
• W2897565443 creator A5085112349 @default.
• W2897565443 date "2018-10-09" @default.
• W2897565443 modified "2023-09-28" @default.
• W2897565443 title "A Comparative Study of Muscle Symptoms of Atorvastatin with Rosuvastatin in Patients of Atherosclerotic Cardiovascular Disease" @default.
• W2897565443 doi "https://doi.org/10.3329/uhj.v14i1.38481" @default.
• W2897565443 hasPublicationYear "2018" @default.
• W2897565443 type Work @default.
• W2897565443 sameAs 2897565443 @default.
• W2897565443 citedByCount "0" @default.
• W2897565443 crossrefType "journal-article" @default.
• W2897565443 hasAuthorship W2897565443A5001077611 @default.
• W2897565443 hasAuthorship W2897565443A5003431303 @default.
• W2897565443 hasAuthorship W2897565443A5009415605 @default.
• W2897565443 hasAuthorship W2897565443A5010446824 @default.
• W2897565443 hasAuthorship W2897565443A5012533751 @default.
• W2897565443 hasAuthorship W2897565443A5014392312 @default.
• W2897565443 hasAuthorship W2897565443A5018339761 @default.
• W2897565443 hasAuthorship W2897565443A5023019606 @default.
• W2897565443 hasAuthorship W2897565443A5025787924 @default.
• W2897565443 hasAuthorship W2897565443A5026922768 @default.
• W2897565443 hasAuthorship W2897565443A5035235024 @default.
• W2897565443 hasAuthorship W2897565443A5042097310 @default.
• W2897565443 hasAuthorship W2897565443A5056130710 @default.
• W2897565443 hasAuthorship W2897565443A5056459550 @default.
• W2897565443 hasAuthorship W2897565443A5057599788 @default.
• W2897565443 hasAuthorship W2897565443A5057698582 @default.
• W2897565443 hasAuthorship W2897565443A5059169044 @default.
• W2897565443 hasAuthorship W2897565443A5064330411 @default.
• W2897565443 hasAuthorship W2897565443A5074373105 @default.
• W2897565443 hasAuthorship W2897565443A5078062998 @default.
• W2897565443 hasAuthorship W2897565443A5081471788 @default.
• W2897565443 hasAuthorship W2897565443A5081637195 @default.
• W2897565443 hasAuthorship W2897565443A5085112349 @default.
• W2897565443 hasBestOaLocation W28975654431 @default.
• W2897565443 hasConcept C126322002 @default.
• W2897565443 hasConcept C164705383 @default.
• W2897565443 hasConcept C2776418732 @default.
• W2897565443 hasConcept C2776839432 @default.
• W2897565443 hasConcept C2777300911 @default.
• W2897565443 hasConcept C2777482532 @default.
• W2897565443 hasConcept C2778616394 @default.
• W2897565443 hasConcept C2778715236 @default.
• W2897565443 hasConcept C2779379848 @default.
• W2897565443 hasConcept C2780499067 @default.
• W2897565443 hasConcept C36880943 @default.
• W2897565443 hasConcept C71924100 @default.
• W2897565443 hasConcept C90924648 @default.
• W2897565443 hasConceptScore W2897565443C126322002 @default.
• W2897565443 hasConceptScore W2897565443C164705383 @default.
• W2897565443 hasConceptScore W2897565443C2776418732 @default.
• W2897565443 hasConceptScore W2897565443C2776839432 @default.
• W2897565443 hasConceptScore W2897565443C2777300911 @default.
• W2897565443 hasConceptScore W2897565443C2777482532 @default.
• W2897565443 hasConceptScore W2897565443C2778616394 @default.
• W2897565443 hasConceptScore W2897565443C2778715236 @default.
• W2897565443 hasConceptScore W2897565443C2779379848 @default.
• W2897565443 hasConceptScore W2897565443C2780499067 @default.
• W2897565443 hasConceptScore W2897565443C36880943 @default.
• W2897565443 hasConceptScore W2897565443C71924100 @default.
• W2897565443 hasConceptScore W2897565443C90924648 @default.
• W2897565443 hasLocation W28975654431 @default.
• W2897565443 hasOpenAccess W2897565443 @default.
• W2897565443 hasPrimaryLocation W28975654431 @default.
• W2897565443 hasRelatedWork W1795386340 @default.
• W2897565443 hasRelatedWork W1902819862 @default.
• W2897565443 hasRelatedWork W2087332266 @default.
• W2897565443 hasRelatedWork W2298941541 @default.
• W2897565443 hasRelatedWork W2325207180 @default.
• W2897565443 hasRelatedWork W2792430054 @default.
• W2897565443 hasRelatedWork W2885595282 @default.
• W2897565443 hasRelatedWork W2897565443 @default.
• W2897565443 hasRelatedWork W2995943169 @default.
• W2897565443 hasRelatedWork W3014308787 @default.
• W2897565443 isParatext "false" @default.
• W2897565443 isRetracted "false" @default.
• W2897565443 magId "2897565443" @default.

• next